Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Izzy who wrote (4298)	5/13/1998 6:45:00 PM
From: margie	Read Replies (3) of 6136

Agouron has scheduled a seminar on anti-angiogenesis compounds for cancer on Sunday, May 17th during ASCO, American Society of Clinical Oncology. PW expects that the company will review its cancer compounds, including the MMP inhibitor, AG3340. asco.org April prescription data for Viracept- 47,614 New prescriptions: 17482 Refills: 30,132. Viracept Up +1.1% Crixivan- Down -4.1% Invirase Down -13% Norvir- Down - 0.2% Fortovase- Up 9.2% Total PI: Down -1.5% Viracept market share 31% for April, up from 30.2% in March. Percentage Market Share 2/98 3/98 4/98 Viracept Market Share 29.7 30.22 31.04% Total scrips 42132 48637 47614 Crixivan 36.75 36.06 35.1% Total scrips 52132 58032 53805 Norvir 13.308 13.43 13.9% Total scrips 19054 22104 21346 Fortovase 8.5 10.23% 11.4% Total scrips 2068 16471 17454 Invirase 11.6 9.76% 8.6% Total scrips 16453 15707 13162 Invirase Plus Fortovase 20.108 19.99% 19.96% Total Scripts 28521 32178 30616 Total* 141,839 160951 153,381

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next